What exactly is Cabozantinib?

Cabozantinib is a broad-spectrum tyrosine kinase inhibitor (TKI) used to treat a variety of advanced cancers. It targets multiple tumor-related tyrosine kinase receptors, including vascular endothelial growth factor receptor (VEGFR), c-MET receptor, RET receptor, etc., and interferes with tumor angiogenesis, cell proliferation and changes in the tumor microenvironment, thereby achieving the purpose of controlling tumor growth and reducing metastasis. Cabozantinib's multi-target effect enables it to demonstrate excellent efficacy in the treatment of various cancers.

1. Indications:

1. Capsules (used to treat progressive medullary thyroid cancer): Cabozantinib capsules are commonly used to treat metastatic and progressive medullary thyroid cancer (MTC). This type of thyroid cancer often responds poorly to traditional treatments. Cabozantinib improves survival and quality of life by inhibiting the activation of multiple receptors.

2. Tablets (for the treatment of advanced renal cell carcinoma, advanced hepatocellular carcinoma, and thyroid cancer):

1) Advanced renal cell carcinoma (RCC): As a first-line treatment for patients with advanced renal cell carcinoma, cabozantinib tablets can significantly improve survival, especially when combined with the immune checkpoint inhibitor nivolumab, which can effectively enhance the therapeutic effect.

2) Advanced hepatocellular carcinoma (HCC): For patients with advanced hepatocellular carcinoma who have been treated with sorafenib, cabozantinib provides a new treatment option by inhibiting tumor angiogenesis and tumor cell proliferation.

3) Differentiated thyroid cancer (DTC): Cabozantinib can be used as an effective alternative treatment option in patients who have progressed after VEGFR-targeted therapy and are not suitable for radioactive iodine therapy.

Cabozantinib's multi-target effect makes it adaptable to different types of cancer, especially in the treatment of advanced cancer, showing its unique advantages.

Keyword tag:

Cabotinib, Cabozantinib, tyrosine kinase inhibitor, medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, multi-target therapy, cancer treatment

Reference materials:https://go.drugbank.com/drugs/DB08875